

Supporting Information

Synthesis and biological studies of different carbohydrate based prodrugs for their use in the ADEPT-concept

Lutz F. Tietze,* Heiko J. Schuster, Birgit Krewer, Ingrid Schuberth

[*] Institute of Organic and Biomolecular Chemistry, Georg-August-University Göttingen,
Tammannstrasse 2, D-37077 Göttingen (Germany); FAX: +49(0)551-399476;
ltietze@gwdg.de

Table of contents

General	S3
General Experimental Procedures	S3
Synthetic procedure and complete experimental data	
Acetylated Glucose Prodrug (13)	S4
Glucose Prodrug (19)	S6
Lactose Heptaacetate	S7
Lactose trichloroacetimidate (7)	S8
Acetylated Lactose Prodrug (14)	S8
Lactose Prodrug (20)	S9
Cellobiose Heptaacetate	S10
Cellobiose Trichloroacetimidate (8)	S11
Acetylated Cellobiose Prodrug (15)	S12
Cellobiose Prodrug (21)	S13
Acetylated Mannose Prodrug (16)	S14
Mannose Prodrug (22)	S15
Acetylated Rhamnose Prodrugs (17)	S16
Rhamnose Prodrugs (23)	S17
NMR-spectra of all Prodrugs	S19-S38
Tables of the HTCFA <i>in vitro</i> data of all new tested compounds	S39-S41
Graphs of HTCFA <i>in vitro</i> results of all tested compounds	S42
HPLC-MS general facts and all chromatograms including mass specs	S43-S45
Table of analytical data and purity criteria of target and other compounds	S46
Purity and peak attributes of target prodrugs	S47

General. All reactions were performed in flame-dried glassware under an atmosphere of argon. Solvents were dried and purified according to the method defined by Perrin and Armarego. Commercial reagents were used without further purification. Thin-layer chromatography (TLC) was carried out on precoated Alugram SIL G/UV₂₅₄ (0.25 mm) plates from Macherey-Nagel & Co. Column chromatography (CC) was carried out on silica gel 60 from Merck with particle size 0.063–0.200 mm for normal pressure and 0.020–0.063 mm for flash chromatography. IR spectra were determined on a Bruker Vektor 22, UV-VIS spectra on a Perkin-Elmer Lambda 2, and mass spectra on a Finnigan LCQ, Finnigan MAT 95 for EI-HRMS, and a Bruker APEX IV fourier transform ion cyclotron resonance mass spectrometer for ESI-HRMS.

¹H NMR spectra were recorded either on a Varian UNITY-300 MHz, Varian Inova 500 MHz, or Varian Inova 600 MHz. ¹³C-NMR spectra were recorded at 75, 125 or 150 MHz. Spectra were taken at room temperature except otherwise stated in deuterated solvents as indicated using the solvent peak as internal standard.


General procedure for the glycosylation, Boc-deprotection and DNA-binder coupling (GP 1): A solution of the phenol **5** (1.00 equiv.) in dry CH₂Cl₂ (45 mL/mmol) was suspended with freshly activated molecular sieves 4 Å (2.00 g/mmol) and stirred for 30 min at ambient temperature. After addition of the trichloroacetimidate (1.00-1.25 equiv.) and cooling to –20 to –18 °C the promoter BF₃·OEt₂ (0.50 equiv.) in dry CH₂Cl₂ (0.5 mL) was added dropwise and stirred at the given temperature. The end of the reaction was controlled by TLC and subsequently excess BF₃·OEt₂ (3.00 equiv.) in CH₂Cl₂ (2.0 mL) added, warmed to 25 °C and stirred for the given time. The reaction mixture was filtered through a small celite pad, thoroughly washed with CH₂Cl₂, the solvent removed and the resulting foam dried under high vacuum for 1 h. The formed salt was dissolved in DMF (65 mL/mmol), the stirred solution cooled to 0 °C and EDC·HCl (3.0 equiv.) followed by DMAI-HCl (**12**) (1.5 equiv.) added. After stirring at 25 °C for 15-30 h the mixture was diluted with EtOAc (70 mL/mmol), Wasser (70 mL/mmol) and satd. NaHCO₃-solution (25 mL), the phases separated and water-layer extracted again with EtOAc (4 × 100 mL/mmol). The combined organic layers were washed with satd. NaCl-solution (4 × 60 mL/mmol), dried over MgSO₄ and the solvent concentrated in vacuo. The crude material was purified by column chromatography (CC) on silica gel (CH₂Cl₂/MeOH = 10:1) to yield the acetylated prodrugs.

General procedure for the Zemplén deactylation (GP 2): A solution of the acetylated prodrugs (1.0 equiv.) in MeOH (individual amounts) was treated at 0 °C with NaOMe-solution (30%-ig in MeOH, 0.15-3.0 equiv.) in MeOH (100 µl) and stirred at ambient

temperature till complete conversion (TLC-control). The mixture was neutralised with HCl (1 M in MeOH from acetylchloride-MeOH) or acetic acid, silica gel (1.5 mg/mg crude material) added and the solvents removed in vacuo. The crude materials were purified by column chromatography (CC) on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 1:1$) and filtered through a membrane-filter or purified by RP-HPLC if necessary.

General Procedure for the synthesis of trichloroacetimides using polymer-supported DBU (GP 3): To a solution of the anomeric free sugar (1.0 equiv.) in CH_2Cl_2 (8-9 mL/mmol) was added polymer-supported 1,8-Diazabicyclo[5.4.0]undec-7ene (PS-DBU, 0.5 mmol/g, 0.5 equiv.) followed by trichloroacetonitrile (4.0 equiv.). The suspension was stirred at 25 °C for the given time, filtered over celite, and the solvents removed without heating under vaccum. Codestillation with benzol (3×50 mL/mmol) afforded the trichloroacetimides as pure compounds. **7** and **8** are stable at 25 °C for several months without decomposition.

**(+)-(1*S*,10*R*)-1-(10-Chloro-ethyl)-3-[(5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]-2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranoside
((+)-13):**




According to GP 1 the glucose trichloroacetimidate **6** (50.9 mg, 110 μ mol, 1.1 equiv.) in CH_2Cl_2 (4.5 mL), phenol (+)-(1*S*,10*R*)-**5** (34.6 mg, 100 μ mol, 1.0 equiv.) and molecular sieves 4 \AA (200 mg) were allowed to react under $\text{BF}_3\cdot\text{OEt}_2$ (7.1 μ L, 50.0 μ mol, 0.5 equiv.) catalysis at -15 $^{\circ}\text{C}$ for 3.0 h. Additional $\text{BF}_3\cdot\text{OEt}_2$ (42.6 μ L, 300 μ mol, 3.0 equiv.), 2.5 h at 25 $^{\circ}\text{C}$, work-up, subsequent reaction with DMAI-HCl (**12**) (42.7 mg, 150 μ mol, 1.5 equiv.) and EDC-HCl (57.5 mg, 300 μ mol, 3.0 equiv.) for 18 h gave crude material that was purified by CC to afford the title compound (+)-**13** (42.2 mg, 52.5 μ mol, 53%) as colourless solid.

R_f = 0.36 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ = 10:1); $[\alpha]_D^{20} = +4.0^{\circ}$ ($c = 0.4$, DMSO); UV (MeOH): λ_{\max} ($\lg \epsilon$) = 206.5 nm (1.8065), 299.0 (1.6167), 334.5 (1.6077); IR (KBr): $\tilde{\nu}$ (cm^{-1}) = 3458, 2946, 1750, 1627, 1520, 1463, 1414, 1231, 1040, 764; $^1\text{H-NMR}$ (599.8 MHz, DMSO-d₆, 35 $^{\circ}\text{C}$): δ = 1.64 (d, $J = 6.6$ Hz, 3 H, H₃₋₁₁), 2.01, 2.03, 2.05 (3 \times s, 12 H, 4 \times COCH₃), 2.26 (s, 6 H, NMe₂), 2.68 (t, $J = 5.8$ Hz, 2 H, H_{2-2''}), 4.07 (m_c, 3 H, H_{2-1''}, H-6_{b''}), 4.25 (m_c, 2 H, H-1, H-5'''), 4.31 (dd, $J = 11.8, 4.4$ Hz, 1 H, H-6_{a'''}), 4.63 (dd, $J = 11.0, 1.7$ Hz, 1 H, H-2_a), 4.76 (m_c, 1 H, H-2_b), 4.80 (dq, $J = 12.8, 6.2, 2.4$ Hz, 1 H, H-10), 5.10 (t, $J = 9.6$ Hz, 1 H, H-4'''), 5.30 (dd, $J = 9.7, 8.0$ Hz, 1 H, H-2''), 5.51 (t, $J = 9.5$ Hz, 1 H, H-3'''), 5.64 (d, $J = 7.4$ Hz, 1 H, H-1'''), 6.93 (dd, $J = 8.9, 2.4$ Hz, 1 H, H-6'), 7.17 (s_{br}, 1 H, H-3'), 7.18 (d, $J = 2.2$ Hz, 1 H, H-4'), 7.42 (d, $J = 8.9$ Hz, 1 H, H-7'), 7.47 (t, $J = 7.6$ Hz, 1 H, H-7), 7.59 (t, $J = 7.6$ Hz, 1 H, H-8), 7.98, 8.00 (2 \times d, $J = 8.1$ Hz, 2 H, H-6, H-9), 8.22 (s, 1 H, H-4), 11.58 (s, 1 H, NH); $^{13}\text{C-NMR}$ (125.7 MHz, DMSO-d₆, 35 $^{\circ}\text{C}$): δ = 20.21, 20.27, 20.32 (4 \times COCH₃), 23.31 (11-CH₃), 45.41 (N(CH₃)₂), 45.87 (C-1), 52.20 (C-2), 57.72 (C-2'''), 61.18 (C-10), 61.35 (C-6'''), 66.17 (C-1''), 67.93 (C-4'''), 70.88 (C-2''', C-5'''), 71.71 (C-3'''), 98.62 (C-1'''), 102.7 (C-4), 103.2 (C-4'), 105.5 (C-3'), 113.2 (C-7'), 115.9 (C-6'), 120.3 (C-5a), 122.0 (C-6), 122.6 (C-9b), 123.2 (C-9), 124.3 (C-7), 127.4, 127.5 (C-8, C-3a'), 129.4, 130.7, 131.8 (C-2', C-7a', C-9a), 141.8 (C-3a), 152.5, 153.0 (C-5, C-5'), 160.2 (NC=O), 169.2, 169.3, 169.4, 170.0 (4 \times COCH₃); MS (ESI): m/z (%) = 809.3 (68) [M + H]⁺, 1636.6 (75) [2M + Na]⁺;

806.4 (78) [M - H]⁻, 1614.2 (86) [2M - H]⁻; **HRMS** C₄₁H₄₆ClN₃O₁₂: calcd. 808.28428; found 808.28419 [M + H]⁺.


(-)-(1*S*,10*R*)-1-(10-Chloro-ethyl)-3-[(5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]- β -D-glucopyranoside ((-)19):



Following GP 2 (+)-13 (165 mg, 204 μ mol, 1.0 equiv.) in MeOH (30.0 mL) was treated with NaOMe (5.51 mg, 19.4 μ L, 18.6 μ mol, 0.5 equiv.) and stirred for 3.0 h. Work-up and CC gave the title compound (**-**)19 as slightly ocher-coulooured solid (106.5 mg, 166 μ mol, 82%).


R_f = 0.26 (CH₂Cl₂/MeOH = 1:1); $[\alpha]_D^{20} = -24.0^\circ$ (c = 0.4, DMSO); **UV** (MeOH): λ_{max} (lg ε) = 204.5 nm (1.6169), .299.0 (1.3426), 333.0 (1.3167); **IR** (KBr): $\tilde{\nu}$ (cm⁻¹) = 3407, 2925, 1623, 1516, 1462, 1415, 1288, 1233, 1178, 1074, 760; **¹H-NMR** (599.8 MHz, DMSO-d₆, 35 °C): δ = 1.65 (d, *J* = 6.5 Hz, 3 H, H₃-11), 2.24 (s, 6 H, NMe₂), 2.66 (t, *J* = 5.7 Hz, 2 H, H₂-2'''), 3.30 (m_c, 1 H, H-5'''), 3.34 (t, *J* = 9.0 Hz, 1 H, H-3'''), 3.39 (t, *J* = 9.0 Hz, 1 H, H-4'''), 3.47 (m_c, 1 H, H-2'''), 3.66 (dd, *J* = 11.3, 2.5 Hz, 1 H, H-6_b'''), 3.75 (d, *J* = 11.0 Hz, 1 H, H-6_a'''), 4.07 (t, *J* = 5.8 Hz, 1 H, H₂-1''), 4.26 (d, *J* = 9.0 Hz, 1 H, H-1), 4.37 (s_{br}, 1 H, OH), 4.63 (d, *J* = 11.8 Hz, 1 H, H-2_b), 4.75 (t, *J* = 9.9 Hz, 1 H, H-2_a), 4.83 (m_c, 2 H, H-10), 4.99 (d, *J* = 7.3 Hz, 1 H, H-1'''), 5.15, 5.40 (2 \times s_{br}, 3 H, 3 \times OH), 6.93 (dd, *J* = 8.8, 2.0 Hz, 1 H, H-6'), 7.18 (m_c, 2 H, H-3', H-4'), 7.40 (d, *J* = 8.8 Hz, 1 H, H-7'), 7.43, 7.58 (t, *J* = 7.5 Hz, 2 H, H-7, H-8), 7.96, 8.35 (2 \times d, *J* = 8.3 Hz, 2 H, H-6, H-9), 8.24 (s, 1 H, H-4), 11.60 (s, 1 H, NH); **¹³C-NMR** (150.8 MHz, DMSO-d₆, 35 °C): δ = 23.36 (11-CH₃), 45.51 (N(CH₃)₂), 45.93 (C-1), 52.20 (C-2), 57.79 (C-2''), 60.72 (C-6'''), 61.34 (C-10), 66.28 (C-1''), 66.51 (C-4'''), 70.07 (C-2'''), 71.01 (C-3'''), 75.38 (C-5'''), 98.43 (C-1'''), 100.9 (C-4), 103.3 (C-4'), 105.5 (C-3'), 113.1 (C-7'), 115.9 (C-6'), 118.7 (C-5a), 122.5 (C-9), 122.8 (C-9b), 123.2 (C-6), 123.9 (C-7), 127.3 (C-8), 127.5 (C-3a'), 129.6, 130.8, 131.7 (C-2', C-7a', C-9a), 142.0 (C-3a), 151.8, 153.0 (C-5, C-5'), 160.1 (NC=O); **MS** (ESI): *m/z* (%) = 640.3 (100) [M + H]⁺, 662.2 (21) [M + Na]⁺; **HRMS** C₃₃H₃₈ClN₃O₈: calcd. 640.24202; found 640.24194 [M + H]⁺.

2,3,4,6-Tetra-*O*-acetyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-acetyl- α / β -D-glucopyranose (Lactose heptaacetate)



α -anomer: $R_f = 0.11$ (pentane/EtOAc = 1:1); **$^1\text{H-NMR}$** (300.5 MHz, CDCl₃): $\delta = 1.94, 2.01, 2.02, 2.03, 2.05, 2.10, 2.13$ ($7 \times$ s, 21 H, $7 \times$ COCH₃), 3.74 (t, $J = 9.5$ Hz, 1 H, H-4), 3.86 (t, $J = 6.8$ Hz, 1 H, H-5'), 3.95-4.23 (m, 4 H, H-5, H-6_b, H-6_{a'}, H-6_{b'}), 4.46 (m, 1 H, H-6_a), 4.48 (d, $J = 7.9$ Hz, 1 H, H-1'), 4.79 (dd, $J = 10.2, 3.6$ Hz, 1 H, H-2), 4.93 (dd, $J = 10.4, 3.4$ Hz, 1 H, H-3'), 5.09 (dd, $J = 10.4, 7.9$ Hz, 1 H, H-2'), 5.35 (m_c, 2 H, H-1, H-4'), 5.49 (t, $J = 9.7$ Hz, 1 H, H-3); **$^{13}\text{C-NMR}$** (75.7 MHz, CDCl₃): $\delta = 20.46, 20.58, 20.70, 20.82, 20.84$ ($7 \times$ COCH₃), 60.74 (C-6'), 61.82 (C-6), 66.55 (C-4'), 68.03 (C-3), 69.02 (C-2'), 69.51 (C-2), 70.51 (C-5'), 70.96 (C-5), 71.27 (C-3'), 76.25 (C-4), 89.93 (C-1), 100.90 (C-1'), 169.0, 169.6, 170.1, 170.2, 170.3, 170.4, 170.5 ($7 \times$ COCH₃); **C₂₆H₃₆O₁₈** (636.55).

2,3,4,6-Tetra-*O*-acetyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-acetyl- α -D-glucopyranose trichloracetimidate (Lactose trichloroacetimidate) (7)




The anomeric free lactoside (2.02 g, 3.17 mmol, 1.00 equiv.) in CH₂Cl₂ (30.0 mL) was treated with PS-DBU (3.10 g, 1.55 mmol, 0.49 equiv.) and trichloroacetonitrile (1.83 g, 1.27 mL, 12.8 mmol, 4.00 equiv.) and stirred for 3 h according to GP 3 giving a colourless foam (2.44 g, 3.12 mmol, 99%).

$R_f = 0.32$ (pentane/EtOAc = 1:1); $[\alpha]_D^{20} = -11.8^\circ$ ($c = 0.5$, MeOH); **UV** (CH₃CN): λ_{\max} (lg ϵ) = 204.5 nm (0.5472), 299.0 (0.3436), 334.5 (0.3287); **IR** (KBr): $\tilde{\nu}$ (cm⁻¹) = 3417, 2943, 1756, 1626, 1593, 1518, 1461, 1411, 1371, 1231, 1173, 1042, 905, 762, 600; **$^1\text{H-NMR}$** (300.5 MHz, CDCl₃): $\delta = 1.94, 1.99, 2.02, 2.04, 2.09, 2.13$ ($6 \times$ s, 21 H, $7 \times$ COCH₃), 3.79-3.90 (m, 2 H, H-4, H-5'), 4.02-4.17 (m, 4 H, H-5, H-6_b, H-6_{a'}, H-6_{b'}), 4.46 (dd, $J = 11.1, 3.5$ Hz, 1 H, H-6_a), 4.50 (d, $J = 7.9$ Hz, 1 H, H-1'), 4.93 (dd, $J = 10.4, 3.4$ Hz, 1 H, H-3'), 5.03 (dd, $J = 10.2, 3.8$ Hz, 1 H, H-2), 5.10 (dd, $J = 10.4, 7.9$ Hz, 1 H, H-2'), 5.33 (dd, $J = 3.4, 0.9$ Hz, 1 H, H-4'), 5.54 (t, $J = 9.8$ Hz, 1 H, H-3), 6.46 (d, $J = 3.8$ Hz, 1 H, H-1), 8.65 (s_{br},

1 H, NH); **¹³C-NMR** (125.7 MHz, CDCl₃): δ = 20.39, 20.42, 20.55, 20.72, 20.79 (7 × COCH₃), 60.73 (C-6'), 61.45 (C-6), 66.55 (C-4'), 69.08 (C-2'), 69.15 (C-3), 69.90 (C-2), 70.66 (C-5'), 70.86 (C-5), 71.05 (C-3'), 75.81 (C-4), 90.62 (CCl₃), 92.83 (C-1), 101.12 (C-1'), 160.9 (C=NH), 169.0, 169.3, 170.0, 170.1, 170.2, 170.3 (7 × COCH₃); **MS** (ESI): *m/z* (%) = 802.0 (56) [M + Na]⁺, 1582.3.0 (100) [2M + Na]⁺; C₂₈H₃₆O₁₈NCl₃ (780.96).

(+)-(1S,10R)-1-(10-Chloro-ethyl)-3-[(5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-acetyl-β-D-glucopyranoside ((+)-14):




According to GP 1 the lactose trichloroacetimidate **7** (117 mg, 149 μmol, 1.15 equiv.) in CH₂Cl₂ (4.0 mL), phenol (+)-(1S,10R)-**5** (45.0 mg, 130 μmol, 1.0 equiv.) and molecular sieves 4 Å (200 mg) were allowed to react under BF₃·OEt₂ (8.2 μl, 65.0 μmol, 0.5 equiv.) catalysis at -16 °C for 3.0 h. Additional BF₃·OEt₂ (41.0 μl, 390 μmol, 3.0 equiv.), 2.0 h at 25 °C, work-up, subsequent reaction with DMAI·HCl (**12**) (59.2 mg, 208 μmol, 1.5 equiv.) and EDC·HCl (74.7 mg, 390 μmol, 3.0 equiv.) for 15 h gave crude material that was purified by CC to afford the title compound **(+)-14** (98.7 mg, 90.1 μmol, 69%) as colourless solid.

R_f = 0.29 (CH₂Cl₂/MeOH = 10:1); [α]_D²⁰ = +4.0 ° (c = 0.3, MeOH); **UV** (CH₃CN): λ_{max} (lg ε) = 206.0 nm (0.5228), 299.0 (0.3291), 335.5 (0.3143); **IR** (KBr): $\tilde{\nu}$ (cm⁻¹) = 2940, 1754, 1627, 1593, 1518, 1461, 1371, 1230, 1060, 762, 602; **¹H-NMR** (599.7 MHz, DMSO-d₆, 35 °C): δ = 1.64 (d, *J* = 6.6 Hz, 3 H, CH₃-11), 1.91, 2.03, 2.04, 2.06, 2.11 (5 × s, 21 H, 7 × COCH₃), 2.28 (s, 6 H, NMe₂), 2.71 (t, *J* = 5.7, 2 H, H-2''), 4.00 (t, *J* = 9.4 Hz, 1 H, H-4'''), 4.04-4.11 (m, 1 H, H-6_b'''), 4.09 (t, *J* = 5.8 Hz, 2 H, H-1''), 4.14 (m, 1 H, H-5'''), 4.19-4.27 (m, 3 H, H-1, H-6_a''', H-6_a'''), 4.35 (d, *J* = 11.3 Hz, 1 H, H-6_b''), 4.63 (dd, *J* = 10.9, 1.1 Hz, 1 H, H-2_a), 4.75 (d, *J* = 10.6 Hz, 1 H, H-2_b), 4.79 (m, 1 H, H-10), 4.81 (t, *J* = 8.0 Hz, 1 H, H-1'''), 4.89 (t, *J* = 10.2, 8.1 Hz, 1 H, H-2'''), 5.19 (dd, *J* = 10.3, 3.5 Hz, 1 H, H-3'''), 5.22 (dd, *J* = 9.7, 8.1 Hz, 1 H, H-2''), 5.26 (d, *J* = 3.4 Hz, 1 H, H-4'''), 5.40 (t, *J* = 9.4 Hz, 1 H, H-3''), 5.58 (d, *J* = 7.9 Hz, 1 H, H-1''), 6.94 (dd, *J* = 8.9, 2.3 Hz, 1 H,

H-6'), 7.17 (d, J = 1.2 Hz, 1 H, H-4'), 7.18 (d, J = 2.0 Hz, 1 H, H-4'), 7.42 (d, J = 8.9 Hz, 1 H, H-7'), 7.46 (t, J = 7.6 Hz, 1 H, H-7), 7.58 (t, J = 7.3 Hz, 1 H, H-8), 7.96 (d, J = 8.5 Hz, 1 H, H-9), 7.99 (d, J = 8.4 Hz, 1 H, H-6), 8.19 (s_{br}, 1 H, H-4), 11.55 (s_{br}, 1 H, NH); ¹³C-NMR (150.8 MHz, DMSO-d₆, 35 °C): δ = 20.12, 20.17, 20.22, 20.31, 20.36, 20.40 ($7 \times$ COCH₃), 23.33 (11-CH₃), 45.33 (N(CH₃)₂), 45.92 (C-1), 52.30 (C-2), 57.65 (C-2''), 60.80 (C-6'''), 61.19 (C-10), 61.95 (C-6'''), 66.06 (C-1''), 67.04 (C-4'''), 68.94 (C-2'''), 69.69 (C-5'''), 70.32 (C-3'''), 71.27 (C-2''), 71.96 (C-3'', C-5''), 75.92 (C-4''), 98.48 (C-1''), 99.87 (C-1'''), 102.9 (C-4), 103.3 (C-4'), 105.5 (C-3'), 113.2 (C-7'), 115.9 (C-6'), 120.3 (C-5a), 122.0 (C-9), 122.7 (C-9b), 123.2 (C-6), 124.3 (C-7), 127.4 (C-8, C-3a'), 129.4, 130.8, 131.8 (C-2', C-7a', C-9a), 141.8 (C-3a), 152.6, 152.9 (C-5, C-5'), 160.3 (NC=O), 169.0, 169.2, 169.4, 169.8, 170.4 ($7 \times$ COCH₃); MS (ESI): m/z (%) = 1096.45 (100) [M + H]⁺; HRMS C₅₃H₆₂ClN₃O₂₀: calcd. 1096.36880; found 1096.36907 [M + H]⁺.

(1*S*,10*R*)-1-(10-Chloro-ethyl)-3-[(5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]-(β 1→4)- β -D-glucopyranoside (20):




Following GP 2 (+)-**14** (67.0 mg, 61.1 μmol, 1.0 equiv.) in MeOH (8 mL) was treated with NaOMe (11.6 mg, 41 μL, 214 μmol, 3.5 equiv., in 1 mL MeOH) and stirred for 5.0 h. Work-up with acetic acid and RP-HPLC gave the title compound **20** as colourless solid (36.7 mg, 45.8 μmol, 75%).

R_f = 0.22 (CH₂Cl₂/MeOH = 1:1.5); UV (CH₃CN): λ_{max} (lg ε) = 206.0 nm (0.5228), 299.0 (0.3291), 335.5 (0.3143); IR (KBr): $\tilde{\nu}$ (cm⁻¹) = 2940, 1754, 1627, 1593, 1518, 1461, 1371, 1230, 1060, 762, 602; ¹H-NMR (599.7 MHz, DMSO-d₆, 35 °C): δ = 1.65 (d, J = 6.6 Hz, 3 H, CH₃-11), 2.27 (s, 6 H, NMe₂), 2.69 (t, J = 5.8 Hz, 2 H, H-2''), 3.35 (dd, J = 9.5, 3.5 Hz, 1 H, H-3'''), 3.38 (dd, J = 9.5, 7.5 Hz, 1 H, H-2'''), 3.50 (t, J = 6.1 Hz, 1 H, H-5'''), 3.46-3.64 (m, 5 H, H-2'', H-3'', H-5''', H-6_{a,b}'''), 3.66 (d, J = 2.7 Hz, 1 H, H-4'''), 3.82 (m_c, 1 H, H-6_{a,b}'''), 4.08 (t, J = 5.9 Hz, 2 H, H-1''), 4.25 (dt, J = 9.4, 2.4 Hz, 1 H, H-1), 4.39-4.61 (br,

6 H, 6 × OH), 4.31 (d, $J = 7.5$ Hz, 1 H, H-1'''), 4.63 (dd, $J = 10.9, 1.6$ Hz, 1 H, H-2_a), 4.76 (d, $J = 9.7$ Hz, 1 H, H-2_b), 4.82 (ddd, $J = 8.9, 6.4, 1.9$ Hz, 1 H, H-10), 5.03 (s_{br}, 1 H, H-1'''), 5.60 (s_{br}, 1 H, OH), 6.92 (dd, $J = 8.9, 2.3$ Hz, 1 H, H-6'), 7.17 (s_{br}, 1 H, H-3'), 7.18 (d, $J = 2.2$ Hz, 1 H, H-4'), 7.40 (d, $J = 8.9$ Hz, 1 H, H-7'), 7.44 (t, $J = 7.6$ Hz, 1 H, H-7), 7.57 (t, $J = 7.6$ Hz, 1 H, H-8), 7.97 (d, $J = 8.4$ Hz, 1 H, H-9), 8.24 (s_{br}, 1 H, H-4), 8.35 (d, $J = 8.5$ Hz, 1 H, H-6), 11.60 (s_{br}, 1 H, NH); ¹³C-NMR (150.8 MHz, DMSO-d₆, 35 °C): $\delta = 23.36$ (11-CH₃), 45.40 (N(CH₃)₂), 45.91 (C-1), 52.03 (C-2), 57.69 (C-2''), 59.79 (C-6'''), 60.40 (C-6'''), 61.31 (C-10), 66.12 (C-1''), 68.13 (C-4'''), 70.58 (C-2'''), 73.09 (C-5'''), 73.20 (C-3'''), 74.74, 74.94 (C-2'', C-3''), 75.51 (C-5''), 79.41 (C-4''), 101.2 (C-1''), 102.0 (C-4), 103.3 (C-4'), 103.7 (C-1'''), 105.4 (C-3'), 113.3 (C-7'), 115.9 (C-6'), 119.0 (C-5a), 122.9 (C-9), 122.9 (C-6), 123.3 (C-9b), 123.7 (C-7), 127.3 (C-3a'), 127.5 (C-8), 129.4, 130.8, 131.7 (C-2', C-7a', C-9a), 142.0 (C-3a), 152.9, 153.3 (C-5, C-5'), 160.1 (NC=O); MS (ESI): m/z (%) = 802.3 (100) [M + H]⁺; HRMS C₃₉H₄₈ClN₃O₁₃: calcd. 802.29484; found 802.29496 [M + H]⁺.


Chromatographic purification of crude 20: A solution of 60.0 mg of crude **20** in 3.00 mL CH₃CN/H₂O = 1:1 + 0.05% HOAc was separated (injection volume 0.50 mL) by semipreparative RP-HPLC (Kromasil 100 C18, 250 × 20 mm, particle size: 7 μm, isocratic CH₃CN/H₂O = 1:3 + 0.05% HOAc, flow: 12 mL·min⁻¹; UV-detector: $\lambda = 299$ nm, Jasco-module) to provide pure **20** ($t_R = 5.6$ min).

2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl-(1→4)-2,3,6-tri-O-acetyl- α / β -D-glucopyranose (Celllobiose heptaacetate)



α -anomer: $R_f = 0.15$ (pentane/EtOAc = 1:1); ¹H-NMR (300.5 MHz, CDCl₃): $\delta = 1.99, 2.01, 2.03, 2.04, 2.08, 2.10, 2.14$ (7 × s, 21 H, 7 × COCH₃), 2.98 (s_{br}, 1 H, OH), 3.68 (ddd, $J = 9.5, 4.0, 2.0$ Hz, 1 H, H-5'), 3.75 (t, $J = 9.5$ Hz, 1 H, H-4), 4.01-4.21 (m, 3 H, H-5, H-6_a, H-6_{a'}), 4.39 (dd, $J = 12.4, 4.1$ Hz, 1 H, H-6_b'), 4.53 (m_c, 1 H, H-6_b), 4.54 (d, $J = 7.9$ Hz, 1 H, H-1'), 4.81 (dd, $J = 10.2, 3.6$ Hz, 1 H, H-2), 4.93 (dd, $J = 10.4, 8.1$ Hz, 1 H, H-2'), 5.08 (t, $J = 9.4$ Hz, 1 H, H-4'), 5.16 (t, $J = 9.3$ Hz, 1 H, H-3'), 5.36 (d, $J = 3.6$ Hz, 1 H, H-1), 5.50 (t, $J = 9.0$ Hz, 1 H, H-3); ¹³C-NMR (75.5 MHz, CDCl₃): $\delta = 20.43, 20.51, 20.55, 20.62, 20.64, 20.79$ (7 × COCH₃), 61.45, 61.68 (C-6, C-6'), 67.67 (C-4'), 67.95 (C-5), 69.23 (C-3), 71.20 (C-2), 71.49 (C-2'), 71.73 (C-5'), 72.86 (C-3'), 76.43 (C-4), 89.82 (C-1), 100.5 (C-1'), 169.0, 169.2, 169.7, 170.2, 170.3, 170.4, 170.5 (7 × COCH₃); C₂₆H₃₆O₁₈ (636.55).


2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-acetyl- α -D-glucopyranose trichloracetimidate (Cellobiose trichloroacetimidate) (8):



The anomeric free lactoside (2.02 g, 3.17 mmol, 1.00 equiv.) in CH_2Cl_2 (30.0 mL) was treated with PS-DBU (3.00 g, 1.50 mmol, 0.47 equiv.) and trichloroacetonitrile (1.83 g, 1.27 mL, 12.8 mmol, 4.00 equiv.) and stirred for 3 h according to GP 3 giving a colourless solid (2.32 g, 2.97 mmol, 94%).

$R_f = 0.35$ (pentane/EtOAc = 1:1); $^1\text{H-NMR}$ (300.5 MHz, CDCl_3): $\delta = 1.99, 2.01, 2.02, 2.03, 2.05, 2.10, 2.12$ ($7 \times \text{s}$, 21 H, $7 \times \text{COCH}_3$), 3.68 (ddd, $J = 9.1, 4.0, 2.0$ Hz, 1 H, H-5'), 3.85 (t, $J = 9.7$ Hz, 1 H, H-4), 4.08 (dd, $J = 12.6, 2.0$ Hz, 1 H, H-6_a'), 4.15 (m_c, 1 H, H-5), 4.16 (dd, $J = 12.8, 4.5$ Hz, 1 H, H-6_a), 4.37 (dd, $J = 12.6, 4.2$ Hz, 1 H, H-6_b'), 4.52 (m_c, 1 H, H-6_b), 4.54 (d, $J = 8.1$ Hz, 1 H, H-1'), 4.94 (dd, $J = 9.0, 8.2$ Hz, 1 H, H-2'), 5.07 (dd, $J = 10.2, 3.7$ Hz, 1 H, H-2), 5.09 (t, $J = 9.0$ Hz, 1 H, H-4'), 5.15 (t, $J = 9.1$ Hz, 1 H, H-3'), 5.53 (t, $J = 9.8$ Hz, 1 H, H-3), 6.49 (d, $J = 3.8$ Hz, 1 H, H-1), 8.68 (s_{br}, 1 H, NH); $^{13}\text{C-NMR}$ (75.5 MHz, CDCl_3): $\delta = 20.37, 20.45, 20.50, 20.58, 20.72$ ($7 \times \text{COCH}_3$), 61.28 (C-6), 61.43 (C-6'), 67.58 (C-4'), 69.16 (C-3), 69.74 (C-2), 70.85 (C-5), 71.55 (C-2'), 71.89 (C-5'), 72.94 (C-3'), 76.00 (C-4), 90.56 (CCl_3), 92.73 (C-1), 100.8 (C-1'), 160.8 (C=NH), 169.0, 169.2, 169.3, 169.9, 170.0, 170.2, 170.4 ($7 \times \text{COCH}_3$); MS (ESI): m/z (%) = 802.0 (52) [$\text{M} + \text{Na}]^+$, 1582.3.0 (100) [$2\text{M} + \text{Na}]^+$; $\text{C}_{28}\text{H}_{36}\text{O}_{18}\text{NCl}_3$ (780.94).


(+)-(1*S*,10*R*)-1-(10-Chloro-ethyl)-3-[5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl]carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]-2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside ((+)-15):



A reaction identical to the procedure giving the lactose derivative (**+)-14** using the cellobiose trichloroacetimidate **8** instead afforded the title compound **(+)-15** as colourless foam (95.7 mg, 87.3 μ mol, 67%).

R_f = 0.42 (CH₂Cl₂/MeOH = 10:1); [α]_D²⁰ = -11.8 ° (c = 0.5, MeOH); **UV** (CH₃CN): λ_{max} (lg ε) = 204.5 nm (0.5472), 299.0 (0.3436), 334.5 (0.3287); **IR** (KBr): $\tilde{\nu}$ (cm⁻¹) = 3417, 2943, 1756, 1626, 1593, 1518, 1461, 1411, 1371, 1231, 1173, 1042, 905, 762, 600; **¹H-NMR** (599.7 MHz, CDCl₃): δ = 1.63 (d, *J* = 6.4 Hz, 3 H, CH₃-11), 1.92, 1.98, 2.00, 2.02, 2.03, 2.06 (6 × s, 21 H, 7 × COCH₃), 2.27 (s, 6 H, NMe₂), 2.70 (t, *J* = 5.5, 2 H, H-2''), 3.96 (t, *J* = 9.4 Hz, 1 H, H-4''), 3.97-4.17 (m, 2 H, H-5''', H-6_b''), 4.08 (t, *J* = 5.7 Hz, 2 H, H-1''), 4.14 (m, 1 H, H-5''), 4.20 (dd, *J* = 11.8, 6.0 Hz, 1 H, H-6_a''), 4.26 (m, 1 H, H-1), 4.27 (dd, *J* = 12.7, 4.2 Hz, 1 H, H-6_a''), 4.36 (d, *J* = 11.6 Hz, 1 H, H-6_b''), 4.62 (d, *J* = 10.7 Hz, 1 H, H-2_a), 4.68 (t, *J* = 8.8 Hz, 1 H, H-3'''), 4.75 (d, *J* = 10.6 Hz, 1 H, H-2_b), 4.79 (m, 1 H, H-10), 4.87 (t, *J* = 8.4 Hz, 1 H, H-1'''), 4.91 (t, *J* = 9.8 Hz, 1 H, H-4'''), 5.20 (m, 1 H, H-2''), 5.27 (t, *J* = 9.0 Hz, 1 H, H-2'''), 5.39 (t, *J* = 9.4 Hz, 1 H, H-3''), 5.55 (d, *J* = 7.9 Hz, 1 H, H-1''), 6.93 (d, *J* = 8.6 Hz, 1 H, H-6'), 7.15, 7.17 (2 × s_{br}, 2 H, H-3', H-4'), 7.41 (d, *J* = 8.9 Hz, 1 H, H-7'), 7.46 (t, *J* = 7.4 Hz, 1 H, H-7), 7.50 (t, *J* = 7.2 Hz, 1 H, H-8), 7.94 (d, *J* = 8.4 Hz, 1 H, H-9), 7.99 (d, *J* = 8.4 Hz, 1 H, H-6), 8.17 (s_{br}, 1 H, H-4), 11.53 (s_{br}, 1 H, NH); **¹³C-NMR** (150.8 MHz, CDCl₃): δ = 20.12, 20.17, 20.22, 20.31, 20.36, 20.40 (7 × COCH₃), 23.32 (11-CH₃), 45.38 (N(CH₃)₂), 45.90 (C-1), 52.28 (C-2), 57.69 (C-2''), 61.18 (C-10), 61.45 (C-6''), 61.89 (C-6'''), 66.12 (C-1''), 67.70 (C-4'''), 70.44 (C-5'''), 71.19 (C-2''', C-3'''), 71.69 (C-3''), 71.99 (C-5''), 72.23 (C-2'''), 76.11 (C-4''), 98.52 (C-1''), 99.49 (C-1'''), 102.9 (C-4), 103.2 (C-4'), 105.5 (C-3'), 113.2 (C-7'), 115.9 (C-6'), 120.3 (C-5a), 122.0 (C-9), 122.7 (C-9b), 123.2 (C-6), 124.3 (C-7), 127.4, 127.5 (C-8, C-3a'), 129.4, 130.7, 131.7 (C-2', C-7a', C-9a), 141.8 (C-3a), 152.5, 153.0 (C-5, C-5'), 160.3 (NC=O), 168.9, 169.1, 169.2, 169.4, 169.5, 169.9, 170.4 (7 × COCH₃); **MS** (ESI): *m/z* (%) = 1096.45 (100) [M + H]⁺; **HRMS** C₅₃H₆₂ClN₃O₂₀: calcd. 1096.36880; found 1096.36914 [M + H]⁺.

(1S,10R)-1-(10-Chloro-ethyl)-3-[(5-(2-(N,N-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]-D-glucopyranosyl-(β 1 \rightarrow 4)- β -D-glucopyranoside (21):




Following GP 2 (+)-**15** (65.9 mg, 60.1 μ mol, 1.0 equiv.) in MeOH (8 mL) was treated with NaOMe (11.4 mg, 40 μ L, 210 μ mol, 3.5 equiv., in 1 mL MeOH) and stirred for 1.5 h. Work-up with acetic acid and RP-HPLC gave the title compound **21** as colourless cotton-like solid (24.1 mg, 30.1 μ mol, 50%).

R_f = 0.25 (CH₂Cl₂/MeOH = 1:1.5); **UV** (MeOH): λ_{max} (lg ϵ) = 253.0 nm (1.1978), 297.0 (1.2604), 330.5 (1.2348); **IR** (KBr): $\tilde{\nu}$ (cm^{-1}) = 3386, 2925, 1715, 1623, 1533, 1409, 1212, 1072, 759; **¹H-NMR** (599.7 MHz, DMSO-d₆, 35 °C): δ = 1.65 (d, J = 6.7 Hz, 3 H, CH₃-11), 2.51 (s_{br}, 6 H, NMe₂), 3.00-3.13 (m, 4 H, H-2'', H-2''', H-4'''), 3.17-3.27 (m, 2 H, H-5'', H-5'''), 3.45 (dd, J = 11.4, 6.4 Hz, 1 H, H-6_a'''), 3.48-3.55 (m, 3 H, H-2''', H-3''', H-3'''), 3.62 (t, J = 8.7 Hz, 1 H, H-4'''), 3.73 (dd, J = 11.3, 1.5 Hz, 1 H, H-6_b'''), 3.78 (dd, J = 10.2, 1.6 Hz, 1 H, H-6_a'''), 3.84 (d, J = 11.3 Hz, 1 H, H-6_b''), 4.20 (t, J = 5.4 Hz, 2 H, H-1''), 4.26 (dt, J = 9.3, 2.3 Hz, 1 H, H-1), 4.37 (d, J = 7.9 Hz, 1 H, H-1'''), 4.59 (s_{br}, 2 H, 2 \times OH), 4.62 (dd, J = 11.1, 1.8 Hz, 1 H, H-2_a), 4.75 (d, J = 10.1 Hz, 1 H, H-2_b), 4.78 (s_{br}, 1 H, OH), 4.82 (dq, J = 6.8, 2.5 Hz, 1 H, H-10), 4.96-5.03 (m_{br}, 4 H, H-1''', 3 \times OH), 5.60 (s_{br}, 1 H, OH), 6.96 (dd, J = 8.9, 2.4 Hz, 1 H, H-6'), 7.18 (s_{br}, 1 H, H-3'), 7.21 (d, J = 2.2 Hz, 1 H, H-4'), 7.42 (d, J = 8.8 Hz, 1 H, H-7'), 7.44 (t, J = 8.0 Hz, 1 H, H-7), 7.57 (ddd, J = 8.0, 6.9, 1.1 Hz, 1 H, H-8), 7.97 (d, J = 8.4 Hz, 1 H, H-9), 8.22 (s_{br}, 1 H, H-4), 8.35 (d, J = 8.5 Hz, 1 H, H-6), 11.63 (s_{br}, 1 H, NH); **¹³C-NMR** (150.8 MHz, DMSO-d₆, 35 °C): δ = 20.95 ($\text{CH}_3\text{CO}_2\text{H}$), 23.37 (11-CH₃), 44.36 (N(CH₃)₂), 45.89 (C-1), 52.02 (C-2), 56.84 (C-2''), 59.66 (C-6'''), 61.00 (C-6'''), 61.32 (C-10), 64.78 (C-1''), 70.01 (C-4'''), 73.27 (C-2'''), 73.06, 74.82, 74.97 (C-2''', C-3''', C-3'''), 76.39, 76.76 (C-5''', C-5'''), 101.2 (C-1'''), 103.0 (C-1'''), 103.6 (C-4'), 105.4 (C-3'), 113.2 (C-7'), 115.8 (C-6'), 119.0 (C-5a), 122.9 (C-9, C-9b), 123.3 (C-6), 123.7 (C-7), 127.3 (C-3a'), 127.4 (C-8), 129.4, 131.0, 131.8 (C-2', C-7a', C-9a), 141.9 (C-3a), 152.6, 153.3 (C-5, C-5'), 160.1 (NC=O), 171.9 (CO₂H); **MS** (ESI): m/z (%) = 802.3 (100) [M + H]⁺; **HRMS** C₃₉H₄₈ClN₃O₁₃: calcd. 802.29484; found 802.29482 [M + H]⁺.

Chromatographic purification of crude 21: the same conditions as described for **20** provided pure **21** ($t_R = 4.7$ min).

(+)-(1*S*,10*R*)-1-(10-Chloro-ethyl)-3-[(5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]-2,3,4,6-tetra-*O*-acetyl- α -D-mannopyranoside
((+)-**16**):




According to GP 1 mannose trichloroacetimidate **9** (77.6 mg, 168 μ mol, 1.1 equiv.) in CH_2Cl_2 (7.0 mL), phenol (+)-(1*S*,10*R*)-**5** (52.8 mg, 152 μ mol, 1.0 equiv.) and molecular sieves 4 Å (380 mg) were allowed to react under $\text{BF}_3\cdot\text{OEt}_2$ (9.6 μ l, 76.0 μ mol, 0.5 equiv.) catalysis at -20 °C for 100 min. Additional $\text{BF}_3\cdot\text{OEt}_2$ (57.8 μ l, 456 μ mol, 3.0 equiv.), 2.0 h at 25 °C, work-up, subsequent reaction with DMAI·HCl (**12**) (65.0 mg, 228 μ mol, 1.5 equiv.) and EDC·HCl (87.3 mg, 456 μ mol, 3.0 equiv.) for 15 h gave crude material that was purified by CC to afford the title compound (+)-**16** (80.0 mg, 99.0 μ mol, 65%) as colourless solid.

$R_f = 0.43$ ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 9:1$); $[\alpha]_D^{20} = +77.8^\circ$ ($c = 0.8$, MeOH); $^1\text{H-NMR}$ (599.8 MHz, DMSO-d₆, 35 °C): $\delta = 1.65$ (d, $J = 6.7$ Hz, 3 H, H₃₋₁₁), 1.87, 2.04, 2.19 (3 × s, 12 H, 4 × COCH₃), 2.24 (s, 6 H, NMe₂), 2.64 (t, $J = 5.9$ Hz, 2 H, H-2''), 3.96 (dd, $J = 12.2, 2.4$ Hz, 1 H, H-6_b''), 4.07 (t, $J = 5.9$ Hz, 1 H, H-1''), 4.09 (ddd, $J = 10.0, 5.6, 2.3$ Hz, 1 H, H-5'''), 4.21 (dd, $J = 12.3, 5.7$ Hz, 1 H, H-6_a''), 4.28 (td, $J = 9.3, 2.3$ Hz, 1 H, H-1), 4.64 (dd, $J = 11.0, 2.3$ Hz, 1 H, H-2_a), 4.77 (dd, $J = 10.6, 9.9$ Hz, 1 H, H-2_b), 4.81 (ddd, $J = 13.4, 6.2, 2.4$ Hz, 1 H, H-10), 5.27 (t, $J = 10.1$ Hz, 1 H, H-4'''), 5.55 (dd, $J = 3.5, 1.7$ Hz, 1 H, H-2'''), 5.58 (dd, $J = 10.0, 3.5$ Hz, 1 H, H-3'''), 5.90 (d, $J = 1.1$ Hz, 1 H, H-1'''), 6.93 (dd, $J = 8.9, 2.4$ Hz, 1 H, H-6'), 7.18 (2 × d, $J = 2.2$ Hz, 2 H, H-3', H-4'), 7.40 (d, $J = 8.9$ Hz, 1 H, H-7'), 7.54 (ddd, $J = 8.2, 6.8, 1.1$ Hz, 1 H, H-7), 7.62 (ddd, $J = 8.3, 6.9, 1.2$ Hz, 1 H, H-8), 8.03 (d, $J = 8.4$ Hz, 1 H, H-9), 8.16 (d, $J = 8.5$ Hz, 1 H, H-6), 8.30 (s, 1 H, H-4), 11.56 (s, 1 H, NH); $^{13}\text{C-NMR}$ (125.7 MHz, DMSO-d₆, 35 °C): $\delta = 20.09, 20.31, 20.37, 20.51$ (4 × COCH₃), 23.29 (11-CH₃), 45.49 (N(CH₃)₂), 45.91 (C-1), 51.99 (C-2), 57.77 (C-2''), 61.24 (C-10),

61.66 (C-6'''), 65.22 (C-4'''), 66.28 (C-1''), 68.58 (C-2''', C-3'''), 68.97 (C-3'''), 95.70 (C-1'''), 101.8 (C-4), 103.3 (C-4'), 105.5 (C-3'), 113.1 (C-7'), 115.9 (C-6'), 119.9 (C-5a), 122.0 (C-6), 122.4 (C-9b), 123.3 (C-9), 124.4 (C-7), 127.5 (C-8, C-3a'), 129.6, 130.7, 131.7 (C-2', C-7a', C-9a), 141.8 (C-3a), 151.0, 153.0 (C-5, C-5'), 160.0 (NC=O), 169.4, 169.5, 169.7, 169.8 ($4 \times$ COCH₃); **MS** (ESI): *m/z* (%) = 808.3 (100) [M + H]⁺; **HRMS** C₄₁H₄₆ClN₃O₁₂: calcd. 808.28456; found 808.28428 [M + H]⁺.

(+)-(1*S*,10*R*)-1-(10-Chloro-ethyl)-3-[(5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]- α -D-mannopyranoside ((+)-22):




Following GP 2 **(+)-16** (28.1 mg, 34.8 μ mol, 1.0 equiv.) in MeOH (30 mL) was treated with NaOMe (0.94 mg, 3.3 μ L, 17.4 μ mol, 0.5 equiv.) and stirred for 30 min. Work-up and CC gave the title compound **(+)-22** as colourless solid (18.3 mg, 28.6 μ mol, 82%) which can be crystallised from a minimum amount methanol/ *n*-hexane.

R_f = 0.45 (CH₂Cl₂/MeOH = 1:1); $[\alpha]_D^{20} = +105.0^\circ$ (c = 0.8, MeOH); **UV** (MeOH) λ_{max} (lg ϵ) = 201.5 nm (1.8119), 204.0 (1.7961), 300.0 (1.5398), 331.0 (1.4299); **IR** (KBr): $\tilde{\nu}$ (cm⁻¹) = 3385, 2928, 1624, 1591, 1516, 1461, 1415, 1288, 1265, 1233, 1178, 1120, 1069, 841, 760, 690; **¹H-NMR** (599.8 MHz, DMSO-d₆, 35 °C): δ = 1.65 (d, *J* = 6.7 Hz, 3 H, H-11), 2.24 (s, 6 H, NMe₂), 2.65 (t, *J* = 5.8 Hz, 2 H, H-2''), 3.43 (ddd, *J* = 9.2, 4.4, 2.3 Hz, 1 H, H-5'''), 3.51 (dd, *J* = 11.8, 4.4 Hz, 1 H, H-6_a''), 3.56 (dd, *J* = 11.8, 2.2 Hz, 1 H, H-6_b''), 3.66 (t, *J* = 9.5 Hz, 1 H, H-4''), 3.94 (dd, *J* = 9.3, 3.0 Hz, 1 H, H-3'''), 4.07 (m_c, 3 H, H-1'', H-2'''), 4.23 (dt, *J* = 9.2, 2.2 Hz, 1 H, H-1), 4.38 (s_{br}, 1 H, OH), 4.62 (dd, *J* = 11.0, 2.0 Hz, 1 H, H-2_a), 4.78 (m_c, 2 H, H-10, H-2_b), 4.88, 4.95, 5.20 (3 \times s_{br}, 3 H, 3 \times OH), 5.69 (s_{br}, 1 H, H-1'''), 6.93 (dd, *J* = 8.8, 2.2 Hz, 1 H, H-6'), 7.18 (m_c, 2 H, H-3', H-4'), 7.40 (d, *J* = 8.9 Hz, 1 H, H-7'), 7.46, 7.58 (t, *J* = 8.0 Hz, 2 H, H-7, H-8), 7.97, 8.15 (2 \times d, *J* = 8.1 Hz, 2 H, H-6, H-9), 8.22 (s, 1 H, H-4), 11.60 (s, 1 H, NH); **¹³C-NMR** (150.8 MHz, DMSO-d₆, 35 °C): δ = 23.36 (11-CH₃), 45.51 (N(CH₃)₂), 45.93 (C-1), 52.20 (C-2), 57.79 (C-2''), 60.72 (C-6'''), 61.34 (C-10), 66.28 (C-1''), 66.51 (C-4'''), 70.07 (C-2''), 71.01 (C-3'''), 75.38 (C-5'''), 98.43

(C-1'''), 100.9 (C-4), 103.3 (C-4'), 105.5 (C-3'), 113.1 (C-7'), 115.9 (C-6'), 118.7 (C-5a), 122.5 (C-6), 122.8 (C-9b), 123.2 (C-9), 123.9 (C-7), 127.3 (C-8), 127.5 (C-3a'), 129.6, 130.8, 131.7 (C-2', C-7a', C-9a), 142.0 (C-3a), 151.8, 153.0 (C-5, C-5'), 160.1 (NC=O); **MS** (ESI): m/z (%) = 640.2 (100) $[M + H]^+$, 1280.9 (15) $[2M + H]^+$; **HRMS** $C_{33}H_{38}ClN_3O_8$: calcd. 640.24202; found 640.24211 $[M + H]^+$.

(1SR,10RS)-1-(10-Chloro-ethyl)-3-[(5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]-2,3,4-tri-*O*-acetyl- α -L-rhamnopyranosides (17):




According to GP 1 the rhamnose trichloroacetimidate **10** (66.9 mg, 154 µmol, 1.05 equiv.) in CH₂Cl₂ (7.0 mL), phenol (+/−)-(1*RS*,10*SR*)-**5** (50.7 mg, 146 µmol, 1.0 equiv.) and molecular sieves 4 Å (350 mg) were allowed to react under BF₃·OEt₂ (9.3 µL, 73.2 µmol, 0.5 equiv.) catalysis at −20 °C for 105 min. Additional BF₃·OEt₂ (55.6 µL, 439 µmol, 3.0 equiv.), 1.5 h at 25 °C, work-up, subsequent reaction with DMAI·HCl (**12**) (62.3 mg, 219 µmol, 1.5 equiv.) and EDC·HCl (83.8 mg, 438 µmol, 3.0 equiv.) for 19.5 h gave crude material that was purified by CC to afford the title compound **17** (60.0 mg, 81.0 µmol, 54%) as colourless solids.

R_f = 0.45 (CH₂Cl₂/MeOH = 10:1); **¹H-NMR** (300.1 MHz, DMSO-d₆, 35 °C): δ = 1.16, 1.20 (2 × d, *J* = 6.2 Hz, 3 H, H₃-6), 1.66 (d, *J* = 6.6 Hz, 3 H, H₃-11), 2.04, 2.07, 2.08, 2.17, 2.19 (5 × s, 9 H, 3 × COCH₃), 2.26 (s, 6 H, NMe₂), 2.67 (t, *J* = 5.8 Hz, 2 H, H₂-2''), 4.00 (dq, *J* = 9.8, 6.3 Hz, 1 H, H-5'''), 4.07 (t, *J* = 5.7 Hz, 2 H, H₂-1''), 4.28 (dd, *J* = 6.0, 2.5 Hz, 1 H, H-1), 4.65 (d, *J* = 10.9 Hz, 1 H, H-2_a), 4.75 (d, *J* = 10.0 Hz, 1 H, H-2_b), 4.68-4.78 (m, 1 H, H-10), 5.09, 5.10 (2 × t, *J* = 9.9 Hz, 1 H, H-4''), 5.51-5.58 (m, 2 H, H-2''', H-3'''), 5.78, 5.83 (2 × s_{br}, 1 H, H-1'''), 6.92, 6.95 (2 × s_{br}, 1 H, H-6'), 7.06-7.28 (s_{br}, 2 H, H-3', H-4'), 7.41 (d, *J* = 8.9 Hz, 1 H, H-7'), 7.53 (t, *J* = 7.6 Hz, 1 H, H-7), 7.61 (t, *J* = 7.6 Hz, 1 H, H-8), 8.01 (d, *J* = 8.3 Hz, 1 H, H-9), 8.17 (d, *J* = 8.3 Hz, 1 H, H-6), 8.32, 8.36 (2 × s_{br}, 1 H, H-4), 11.60,


11.64 ($2 \times$ s_{br}, 1 H, NH); **¹³C-NMR** (75.5 MHz, DMSO-d₆, 35 °C): δ = 17.19, 17.23 (C-6'''), 20.39, 20.51 (3 \times COCH₃), 23.28, 23.35 (11-CH₃), 45.41 (N(CH₃)₂), 45.95 (C-1), 51.90, 52.04 (C-2), 57.72 (C-2''), 61.24 (C-10), 66.19 (C-1''), 65.22 (C-4'''), 68.58 (C-2''', C-3'''), 68.97 (C-3'''), 95.69, 96.08 (C-1'''), 101.8, 102.0 (C-4), 103.3 (C-4'), 105.4, 105.5 (C-3'), 113.1 (C-7'), 115.9 (C-6'), 119.7, 119.8 (C-5a), 122.0 (C-6), 122.4, 122.5 (C-9b), 123.3 (C-9), 124.4 (C-7), 127.5 (C-8, C-3a'), 129.6, 130.7, 131.7 (C-2', C-7a', C-9a), 141.9 (C-3a), 151.2, 151.4, 152.9 (C-5, C-5'), 160.1, 162.2 (NC=O), 169.5, 169.6, 169.7 (3 \times COCH₃). **MS:** C₃₃H₃₈ClN₃O₈: calcd. 750.23.

(1*S*,10*R*)-1-(10-Chloro-ethyl)-3-[(5-(2-(*N,N*-dimethylamino)-ethoxy)-indol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indol-5-yl]- α -L-rhamnopyranosides (23):



Following GP 2 (1*S*,10*R*)-**17** (30 mg, 40 μ mol, 1.0 equiv.) in MeOH (30 mL) was treated with NaOMe (1.1 mg, 3.8 μ L, 20 μ mol, 0.94 mg, 0.5 equiv.) and stirred for 30 min. Work-up and CC gave the title compound **23** as slightly yellow solids (20 mg, 32 μ mol, 80%). **R_f** = 0.42 (CH₂Cl₂/MeOH = 1:1); [α]_D²⁰ = -53.3 ° (c = 0.6, MeOH); **UV** (MeOH): λ_{max} (lg ε) = 205.0 nm (1.6310), 242.5 (1.3344), 300.0 (1.4427), 336.0 (1.4121); **IR** (KBr): $\tilde{\nu}$ (cm⁻¹) = 3406, 2927, 1625, 1590, 1516, 1461, 1400, 1288, 1265, 1232, 1178, 1138, 1026, 971, 840, 760, 681; **¹H-NMR** (599.7 MHz, DMSO-d₆, 35 °C): δ = 1.12, 1.19 (2 \times d, *J* = 6.2 Hz, 3 H, H₃-6), 1.65, 1.66 (2 \times d, *J* = 6.5 Hz, 3 H, H₃-11), 2.24 (s, 6 H, NMe₂), 2.66 (t, *J* = 5.8 Hz, 2 H, H-2''), 3.33-3.41 (m, 1 H, H-4'''), 3.54, 3.65 (2 \times dq, *J* = 9.7, 6.3 Hz, 1 H, H-5'''), 3.86, 3.88 (2 \times dd, *J* = 9.2, 3.3 Hz, 1 H, H-3'''), 4.02-4.10 (m_c, 3 H, H-1'', H-2''), 4.25 (dd, *J* = 9.3, 1.9 Hz, 1 H, H-1), 4.63 (2 \times d, *J* = 10.8, 2.2 Hz, 1 H, H-2_a), 4.76-4.85 (m, 3 H, H-2_b, H-10, OH), 4.91, 5.15 (2 \times s_{br}, 2 H, 2 \times OH), 5.50, 5.59 (2 \times s_{br}, 1 H, H-1'''), 6.92 (2 \times dd, *J* = 8.9, 1.9 Hz, 1 H, H-6'), 7.17 (s_{br}, 2 H, H-3', H-4'), 7.29, 7.40 (2 \times d, *J* = 8.9 Hz, 1 H, H-7'), 7.46 (t, *J* = 7.6 Hz, 1 H, H-7), 7.58 (t, *J* = 7.5 Hz, 1 H, H-8), 7.98 (d, *J* = 8.3 Hz, 1 H, H-9), 8.13 (d, *J* = 8.4 Hz, 1 H, H-6), 8.25, 8.32 (2 \times s, 1 H, H-4), 11.59, 11.62 (2 \times s, 1 H, NH); **¹³C-NMR** (125.7 MHz, DMSO-d₆, 35 °C): δ = 17.34, 17.86 (C-6'''), 23.35, 23.39 (11-CH₃), 45.52



(NCH₃)₂), 45.92, 45.95 (C-1), 52.00 (C-2), 57.56, 57.79 (C-2''), 61.34 (C-10), 66.27 (C-1'''), 65.22 (C-4'''), 68.58 (C-2''', C-3'''), 68.97 (C-3'''), 95.69, 96.08 (C-1'''), 101.0, 101.6 (C-4), 103.3 (C-4'), 105.4, 105.5 (C-3'), 113.1 (C-7'), 115.9 (C-6'), 119.7, 119.8 (C-5a), 121.9, 122.0 (C-6), 122.4, 122.5 (C-9b), 122.8, 122.9 (C-9), 124.0 (C-7), 127.3, 127.5 (C-8, C-3a'), 129.6, 130.8, 131.7 (C-2', C-7a', C-9a), 142.0, 142.1 (C-3a), 151.8, 152.3, 153.0 (C-5, C-5'), 160.0, 160.1 (NC=O); **MS** (ESI): *m/z* (%) = 624.3 (100) [M + H]⁺, 1247.5 (8) [2M + H]⁺; **HRMS** C₃₃H₃₈N₃O₇Cl: calcd. 624.24710; found 624.24707 [M + H]⁺.



XY5103 dmso
Schnatter / Tietze / CS

SPCETAL LINES FOR TH= 5.2
RF= 6168.3 RPP= 4964.9

INDEX	FREQ	PPM	HEIGHT
1	21374.7	170.05	24.0
2	21394.5	169.41	22.8
3	21279.9	169.30	23.6
4	21264.0	169.17	23.4
5	20140.4	160.23	22.1 ^{Δε=0}
6	19227.9	152.48	20.7 ^{Δε}
7	19166.2	152.48	11.3 ^{3*}
8	17817.1	141.74	21.4
9	16558.5	131.75	22.7
10	16431.1	130.72	17.9
11	16269.2	129.43	17.0
12	16021.4	127.46	16.0
13	16014.8	127.41	21.5
14	15624.0	124.30	13.1
15	15485.5	123.23	15.0
16	15408.8	122.59	17.6
17	15329.0	121.95	12.7
18	15116.0	120.26	12.0 ⁵
19	14564.7	115.87	15.1 ⁶
20	14231.4	113.74	19.7 ⁴
21	13235.8	105.46	17.0 ⁷
22	12973.6	103.22	17.6 ⁸
23	12911.4	102.72	7.1 ¹⁴
24	12396.3	98.63	20.8 ¹⁴
25	9012.9	71.71	22.5 ¹⁴
26	8909.3	70.98	29.0 ¹⁴
27	8537.9	67.93	15.2 ¹⁴
28	8317.4	66.17	24.6 ¹⁴
29	7711.1	61.35	12.1 ¹⁴
30	7189.0	61.17	14.5 ¹³
31	7254.6	57.72	39.2 ¹³
32	6590.9	52.20	10.4 ²
33	5765.8	45.87	13.8 ⁴
34	5708.0	45.41	102.8 ¹⁴
35	5028.0	40.00	56.8 ¹³
36	5018.3	39.32	11.2
37	5006.8	39.33	38.0 ⁹
38	4997.1	39.76	19.7
39	4986.1	39.67	36.8 ⁷
40	4976.4	39.59	21.4
41	4964.9	39.50	40.7 ⁰
42	4943.8	39.33	3.3 ⁸
43	4923.0	39.17	1.0 ⁸
44	4901.9	39.00	56.7 ³
45	2930.1	23.31	28.4 ¹⁴
46	2553.9	20.32	35.6
47	2347.8	20.27	63.9 ¹⁴
48	2539.8	20.21	28.9 ¹⁴



XY5103 dmso
Schnatter / Tietze / CS

DATE: Feb 1 2006 FILE:nmr-data: tietze/xy5103_5c

xy5106 d6-dmso 35Gradc
Schuster/Tietze

Feb 2 2006

INSTRUMENT INOVA-600

SAMPLE 3ml

OBSERVE H1

Frequency 599.744 MHz

Spectral width 10000.0 Hz

Acquisition time 3.200 sec

Relaxation delay 0.000 sec

Pulse width 45.0 degrees

Temperature 35.0 deg. C / 308.1 K



No. repetitions 32

Double precision acquisition

DATA PROCESSING



PPM 131.072

total acquisition time 1 minutes



xy5106 d6-dmso 35GradC
 Schuster/Tietze
 Feb 2 2006
 INSTRUMENT: INOVA-500
 OBSERVE C13
 Frequency 125.707 MHz
 Spectral width 28901.7 Hz
 Acquisition time 2.714 sec
 Relaxation delay 0.000 sec
 Pulse 30.0 degrees
 Temperature 35.0 deg. C / 308.1 :
 20480 repetitions
 DECOUPLE H1
 Frequency 499.079 MHz
 Power 36 dB
 Decoupler continuously on
 WALTZ-16 modulated
 Double precision acquisition
 DATA PROCESSING
 Line broadening 1.0 Hz
 FID size 112072
 Total acquisition time 12.6 hours



SPECTRAL LINES FOR TH= 4.6
 FROM -2.5 ppm TO 177.5 ppm
 REL= 1203.9 REP= 0.0
 INDEX FREQ. (PPM) HETCOR
 1 2012.7 169.09
 2 19227.3 153.37
 3 19224.8 152.95
 4 17844.9 141.97
 5 16847.9 131.65
 6 16441.6 120.81
 7 16765.2 129.40
 8 16886.3 128.78
 9 16888.5 128.08
 10 16922.2 127.47
 11 15889.6 127.21
 12 15735.6 125.19
 13 15337.6 123.61
 14 15195.7 123.28
 15 15442.8 122.86
 16 14929.4 118.78
 17 15559.9 115.84
 18 14216.3 113.10
 19 14244.4 105.37
 20 13973.1 103.21
 21 13777.8 101.66
 22 13752.6 101.46
 23 9672.2 96.95
 24 9620.6 76.54
 25 9213.6 73.30
 26 8682.6 69.08
 27 8329.4 66.27
 28 7701.1 61.28
 29 7561.1 60.15
 30 7233.4 57.79
 31 6535.8 52.00
 32 5770.2 45.91
 33 5719.0 45.50
 34 5039.0 40.09
 35 5027.5 40.00
 36 5017.8 39.92
 37 5006.8 39.83
 38 4997.1 39.76
 39 4995.6 39.66
 40 4976.4 39.59
 41 4944.5 39.50
 42 4943.8 39.33
 43 4922.6 39.16
 44 4901.9 39.00
 45 2832.8 23.33
 46 2828.9 20.92



xy5106 d6-dmso 35GradC
 Schuster/Tietze

DATE: Feb 2 2006


FILENAME: xy5106_5c




XY5113a dmso-d6
Schuster / Tieze
Feb 14 2007

INSTRUMENT INOVA-500

SAMPLE 3mm
OBSERVE C13
Spectral width 2901.7 Hz
Frequency 125.707 MHz
Acquisition time 2.214 sec
Relaxation delay 0.000 sec
Pulse width 30.0 degrees C / 308.1
Temperature 35.0 deg. C / 130.9
No. repetitions 5120
DECIMATE H1
Frequency 499.879 kHz
Power 36 dB
Decoupler continuously on
WATER-16 modulated
Double precision acquisition
DATA PROCESSING
Line broadening 1.0 Hz
Ft size 111072
Total acquisition time 3:08 hour:
17 15220.0 123.22 20.7 1.4
18 15332.0 121.98 10.2 1.3
19 15119.1 120.28 22.1 1.6
20 14565.2 115.88 17.0 1.0
21 14225.6 113.18 20.0 1.4
22 13262.0 105.51 20.0 1.2
23 12979.3 103.26 19.6 1.5
24 12935.7 102.91 12.4 1.3
25 12552.9 99.87 19.9 1.4
26 12378.7 98.48 19.0 1.3
27 943.0 75.92 16.4 1.3
28 945.5 71.95 26.4 1.2
29 8957.8 71.27 16.3 1.2




SPECTRAL LINES FOR 1H		
INDEX	FREQ PPM	HEIGHT PPM
1	21419.3 21339.9 169.78 45.0	22.9
2	21288.7 169.37 26.3	26.1
3	21235.8 169.43	26.1
4	21265.8 169.19	22.7
5	21235.8 168.95 25.6	25.6
6	21235.8 168.95 25.6	25.6
7	20146.1 160.28	24.7
8	19223.9 152.94 25.9	25.9
9	19175.4 152.56	21.5
10	17824.6 141.81 19.6	19.6
11	16562.0 131.76	131.76
12	16435.0 130.75 26.2	26.2
13	16265.5 127.01 20.9	20.9
14	16232.4 124.28 12.4	12.4
15	15823.4 123.22 11.5	11.5
16	15488.6 122.69 20.7	20.7
17	15220.0 121.98 10.2	10.2
18	15332.0 121.98	121.98
19	15119.1 120.28 22.1	22.1
20	14565.2 115.88 17.0	17.0
21	14225.6 113.18 20.0	20.0
22	13262.0 105.51 20.0	20.0
23	12979.3 103.26 19.6	19.6
24	12935.7 102.91 12.4	12.4
25	12552.9 99.87 19.9	19.9
26	12378.7 98.48 19.0	19.0
27	943.0 75.92 16.4	16.4
28	945.5 71.95 26.4	26.4
29	8957.8 71.27 16.3	16.3



XY5113a dmso-d6
Schuster / Tieze

DATE: Feb 14 2007


FILE: nmrdata: tieze/xy5113a_5c




XY5115 dmso
Schuster / Tietze / CS

Feb 12 2007
INSTRUMENT INNOVA-600
SAMPLE 3mm
OBSERVE C13

Frequency 150.121 MHz
Spectral width 34965.0 Hz
Acquisition time 1.829 sec
Relaxation delay 0.000 sec
Pulse width 33.6 degrees
Temperature 35.0 deg. C /
No. repetitions 2020
DECIMATION 1L
Frequency 59.743 MHz
Power 48 dB
Decoupler continuously on
WALTZ15 modulated
DATA PROCESSING
Line broadening 1.0 Hz
FF size 131072
Total acquisition time 1:01




INDEX	FREQ	PPM	HEIGHT
1	24.45	2	160.11
2	23.116	5	27.19
3	23.016	1	153.29
4	21.007	1	152.93
5	19.859	4	27.4
6	17.729	7	141.96
7	17.515	8	131.69
8	19.223	9	130.83
9	19.192	5	129.41
10	18.655	2	127.48
11	18.537	9	123.70
12	18.537	8	123.70
13	18.534	4	122.93
14	17.949	3	122.93
15	17.747	8	119.02
16	17.063	2	113.15
17	15.993	1	113.15
18	15.631	7	103.66
19	15.510	9	103.66
20	15.383	6	103.66
21	15.194	5	102.01
22	14.423	9	101.20
23	11.301	0	99.41
24	11.301	1	95.53
25	11.301	9	74.24
26	11.039	1	73.74
27	11.039	1	73.74
28	11.023	6	73.09
29	10.643	8	70.58
30	10.274	1	68.13
31	9.921	0	66.12
32	9.246	0	61.21
33	9.108	3	60.20
34	9.017	1	59.79
35	8.700	2	57.69
36	7.846	5	52.03
37	6.923	0	45.91
38	6.846	7	45.40
39	6.037	9	40.04
40	6.019	7	39.92
41	5.998	9	39.78
42	5.977	6	39.64
43	5.956	8	39.50
44	5.936	0	39.36
45	5.914	6	39.22
46	5.893	8	39.08
47	3.522	3	23.36





XY5115 dmso
Schuster / Tietze / CS

Date: Feb 12 2007

FILE:mardast: tietze/xy5115_6c







xy5117 d6-dmso 35GradC
Schuster/Tietze

Oct 9 2007

INSTRUMENT INNOVA-1
PROBE CODE 3mm
OBSERVE C13

FREQUENCY 125.707

SPECTRAL WIDTH 3.0

ACQUISITION TIME 1

RELAXATION DELAY 1

PULSE WIDTH 36.0

TEMPERATURE 35.0

NO. REPETITIONS 32

DECOURLAGE 11

frequency 495.879

power 32 dB

decoupler continuo

WALTZ-16 modulatice

double precision ac

DPA PROCESSING



LINE BROADENING 1.


FT SIZE 131072

TOTAL ACQUISITION 1

SPECTRAL LINES FOR TH= 4.6
FROM -2.5 PPM TO 197.5 PPM
RFLU= 6925.1 RFLP= 4964.9



INDEX	FREQ	PPM	HEIGHT	INDEX	FREQ	PPM	HEIGHT
1	2160.0	171.85	9.9	27	9404.0	74.82	20.8
2	20122.0	160.09	20.3	28	9209.8	73.27	25.9
3	19267.7	153.29	19.2	29	9183.1	73.06	19.7
4	19175.2	152.55	14.4	30	8799.6	70.01	27.0
5	17838.0	141.92	8.6	31	8142.8	64.78	7.2
6	16569.9	131.83	18.0	32	7107.8	61.32	14.8
7	16451.7	130.97	19.5	33	7666.9	61.00	18.7
8	16266.1	129.41	16.9	34	7498.8	59.66	14.4
9	16016.1	127.42	16.7	35	7144.4	56.84	14.0
10	15998.7	127.28	12.3	36	6539.1	52.02	9.5
11	15551.7	123.73	12.3	37	5768.6	45.89	10.4
12	15492.8	123.26	11.6	38	5589.1	44.47	6.3
13	15452.3	122.94	11.9	39	5576.2	44.36	27.7
14	15444.9	122.88	18.6	40	5039.5	40.09	31.2
15	14961.6	119.03	20.2	41	5028.0	40.00	29.7
16	14551.5	115.27	15.6	42	5013.8	39.93	19.7
17	14229.3	113.21	20.2	43	5007.3	39.84	832.5
18	13244.7	105.37	14.8	44	4997.6	39.76	121.7
19	13019.2	103.58	16.5	45	4986.1	39.67	174.7
20	12942.8	102.97	24.3	46	4976.4	39.59	118.2
21	12812.5	101.93	6.4	47	4964.9	39.50	200.0
22	12719.5	101.19	17.6	48	4944.2	39.34	173.5
23	9336.1	79.05	17.0	49	4923.0	39.17	88.9
24	9548.9	76.76	25.4	50	4902.3	39.00	280.7
25	9602.4	76.39	25.8	51	2937.3	23.37	32.7
26	9423.8	74.97	17.5	52	2633.5	20.95	12.3





XY5104 dmso
 Schuster / Tietze / CS
 Feb 7 2006


INSTRUMENT: INOVA-500
OBSERVEZ C13
Frequency 125.707 MHz
Spectral width 24901.7 Hz
Acquisition time 2.214 sec
Relaxation delay 0.000 sec
Pulse 30.0 degrees
Temperature 35.0 deg. C / 306.1
9852 repetitions
DECOPOLIZE III
Frequency 499.879 MHz
Power 36 dB
Decoupler continuously on
MARZIG modulated
Double precision acquisition
DATA PROCESSING
Line broadening 1.0 Hz
FT size 111072
Total Acquisition time 6.1 hours



DATE: Feb 7 2006

XY5104 dmso
 Schuster / Tietze / CS

PRIM:imrcdast: tietze/XY5104_5c



XY5107 dmso
Schuster / Tietze / CS

SPECTRAL LINES FOR TH= 7.2

FROM -2.5 PPM TO 197.5 PPM

RFL= 1703.0 RFL= 0.0

INDEX FBO PPM HEIGHT

1 24146.2 160.12 34.6

2 23067.4 152.95 38.2

3 22887.6 151.77 34.9

4 21410.9 141.98 29.7

5 19851.3 131.68 35.5

6 19723.2 130.83 38.4

7 19546.7 129.62 31.9

8 19229.8 127.51 36.6

9 19156.2 127.29 31.9

10 18659.3 123.95 26.0

11 18574.1 123.17 29.7

12 18513.1 122.77 33.1

13 18410.8 122.48 1

14 17951.1 118.73 27.8

15 17495.1 118.73 33.6

16 17055.0 115.88 34.9

17 15955.4 112.10 43.3

18 15955.4 103.47 42.7

19 15216.0 103.27 42.5

20 14843.2 100.90 33.4

21 14833.2 98.43 44.8

22 11397.3 75.38 45.3

23 10598.9 71.01 46.5

24 10530.8 66.51 46.6

25 9795.6 66.58 64.4

26 9750.8 61.34 35.8

27 9156.3 60.72 41.6

28 8715.1 57.79 91.0

29 7871.6 52.20 30.8

30 6926.7 45.93 42.1

31 6863.8 45.51 223.0

32 6037.4 40.03 12.8

33 6019.7 39.92 117.1

34 5998.4 39.78 341.4

35 5977.6 39.64 681.0

36 5956.8 39.50 800.0


37 5935.5 39.36 675.7

38 5914.6 39.22 345.2

39 5893.8 39.08 116.8

40 4353.6 28.87 8.3

41 3523.4 23.36 66.0



Feb 6 2006
X5107 dmso
Schuster / Tietze / CS

INSTRUMENT INOVA-600

SAMPLE 3mm

OPSERVE C13

Frequency 150.821 MHz

Spectral width 34965.0 Hz

Acquisition time 1.829 sec

Relaxation delay 0.000 sec

Pulse width 35.0 degrees

Temperature 35.0 deg. C / 30

No. repetitions 25504

DECOPPLE H1

Frequency 539.743 MHz

Power 48 dB

Decoupler continuously on

WA122-16 modulated

Double precision acquisition

DATA PROCESSING

Line broadening 1.0 Hz

FT size 131072

Total acquisition time 11:56 :

XY5107 dmso
Schuster / Tietze / CS

SPECTRAL LINES FOR TH= 7.2

FROM -2.5 PPM TO 197.5 PPM

RFL= 1703.0 RFL= 0.0

INDEX FBO PPM HEIGHT

1 24146.2 160.12 34.6

2 23067.4 152.95 38.2

3 22887.6 151.77 34.9

4 21410.9 141.98 29.7

5 19851.3 131.68 35.5

6 19723.2 130.83 38.4

7 19546.7 129.62 31.9

8 19229.8 127.51 36.6

9 19156.2 127.29 31.9

10 18659.3 123.95 26.0

11 18574.1 123.17 29.7

12 18513.1 122.77 33.1

13 18410.8 122.48 1

14 17951.1 118.73 27.8

15 17495.1 118.73 33.6

16 17055.0 115.88 34.9

17 15955.4 112.10 43.3

18 15955.4 103.47 42.7

19 15216.0 103.27 42.5

20 14843.2 100.90 33.4

21 14833.2 98.43 44.8

22 11397.3 75.38 45.3

23 10598.9 71.01 46.5

24 10530.8 66.51 46.6

25 9795.6 66.58 64.4

26 9750.8 61.34 35.8

27 9156.3 60.72 41.6

28 8715.1 57.79 91.0

29 7871.6 52.20 30.8

30 6926.7 45.93 42.1

31 6863.8 45.51 223.0

32 6037.4 40.03 12.8

33 6019.7 39.92 117.1

34 5998.4 39.78 341.4

35 5977.6 39.64 681.0

36 5956.8 39.50 800.0

37 5935.5 39.36 675.7

38 5914.6 39.22 345.2

39 5893.8 39.08 116.8

40 4353.6 28.87 8.3


41 3523.4 23.36 66.0





XY5107 dmso
Schuster / Tietze / CS

DATE: Feb 6 2006

FILE: XY5107_tietze/XY5107_6.cpt









XY5142 d6-dmso 35GradC
Schuster/Tietze

XY5142 d6-dmso 35GradC
Schuster/Tietze
Oct 9 2007



SPECTRAL LINES FOR TH= 4.0
FROM -0.5 PPM TO 197.5 PPM
REFL= 6925.1 RFE= 4944.9

INSTRUMENT	INDOVA-500	INDEX	FREQ	PPM	HEIGHT	INDEX	FREQ	PPM	HEIGHT
PROBE	coldc 3mm	1	20118.8	160.06	15.3	38	8997.3	69.29	34.1
OBSERVE	C13	2	20114.2	160.02	19.1	39	8764.2	69.73	4.3
Frequency	125.707 MHz	3	19224.9	152.95	29.3	40	8330.1	66.27	50.7
Spectral width	30145.9 Hz	4	19138.3	152.26	19.7	41	8295.4	65.99	5.0
Acquisition time	2.112 sec	5	19095.9	151.84	15.8	42	7710.6	61.34	21.0
Relaxation delay	0.000 sec	6	17882.4	142.11	15.2	43	7264.1	57.79	72.8
Pulse width	35.0 degrees	7	17880.9	142.02	12.4	44	57.56	5.8	2.1
Temperature	35.0 deg. C / 308.1 K	8	16548.7	131.66	31.9	45	6335.9	52.00	19.6
No. repetitions	2864	9	16443.3	130.82	22.5	46	5775.5	45.95	22.5
Decouple H1		10	16441.5	130.81	18.4	47	5772.3	45.92	20.5
Frequency	499.879 MHz	11	16291.9	129.62	14.2	48	5721.6	45.52	188.6
Power	32 dB	12	16785.0	123.56	17.2	49	5713.4	45.45	16.5
Decoupler continuously on		13	16116.5	128.22	23.0	50	5709.0	40.09	43.3
WAHMZ-16 modulated		14	16029.0	127.52	23.0	51	5027.5	40.00	143.5
Total acquisition time: 1.41 hours		15	16001.4	127.30	23.1	52	5018.3	39.92	54.4
Line broadening 1.0 Hz		16	15581.2	123.96	22.1	53	5006.8	39.83	43.2
Ft size 131072		17	15484.0	123.19	27.3	54	4997.1	39.76	91.3
DATA PROCESSING		18	15450.4	122.92	17.5	55	4985.6	39.66	85.4
Line broadening 1.0 Hz		19	15431.1	122.77	15.1	56	4976.0	39.59	89.3
Ft size 131072		20	15395.7	122.49	15.5	57	4964.9	39.50	100.0
Total acquisition time: 1.41 hours		21	15390.1	122.44	17.7	58	4954.8	39.42	69.4
Line broadening 1.0 Hz		22	14928.5	118.77	18.7	59	4945.7	39.33	85.9
Ft size 131072		23	14226.2	118.75	20.2	60	4922.6	39.16	42.5
Total acquisition time: 1.41 hours		24	14566.7	115.89	25.5	61	4901.9	39.00	140.9
Line broadening 1.0 Hz		25	14213.2	113.08	41.1	62	3919.6	31.18	5.8
Ft size 131072		26	13595.8	105.46	18.8	63	3664.6	29.15	51.7
Total acquisition time: 1.41 hours		27	13248.4	105.40	22.4	64	3636.5	28.93	21.5
Line broadening 1.0 Hz		28	12979.1	103.26	38.4	65	3631.4	28.89	12.2
Ft size 131072		29	12776.1	101.64	16.1	66	3592.8	28.58	10.3
Total acquisition time: 1.41 hours		30	12703.4	101.07	13.7	67	3584.0	28.51	4.1
Line broadening 1.0 Hz		31	12500.0	99.95	25.2	68	3115.5	24.79	4.1
Ft size 131072		32	12396.8	98.63	18.4	69	2938.6	23.39	33.2
Total acquisition time: 1.41 hours		33	9029.8	71.84	30.7	70	2934.6	23.35	27.1
Line broadening 1.0 Hz		34	9027.0	71.82	25.3	71	2761.9	21.97	10.5
Ft size 131072		35	8894.5	70.76	44.4	72	2249.2	17.89	40.1
Total acquisition time: 1.41 hours		36	8841.1	70.34	28.8	73	2245.5	17.86	33.6
Line broadening 1.0 Hz		37	8834.2	70.28	23.7	74	2178.2	17.34	4.4
Ft size 131072		38	8797.3	69.99	34.1	75	1798.2	13.83	8.7



xy5142 d6-dmso 35GradC
Schuster/Tietze

DATE: Oct 9 2007

FILE:mrmdast: tietze/xy5142_5c

Results for β -D-Glucoside 19:

with β -D-Glucosidase (10 U/ml)		with Cellulase (0.17 U/ml)		without β -D-Glucosidase	
concentration [nM]	Clone formation rate [%] pH = 7.4	concentration [nM]	Clone formation rate [%] pH = 7.4	concentration [nM]	Clone formation rate [%] pH = 7.4
0	100			0	100
0.16	95.97			781	90.78
0.78	93.96	0	100	1172	90.63
1.56	95.3	0.78	83.09	1562	65.39
3.91	112.75	1.56	62.91	2343	39.67
7.81	100.67	3.91	14.87	3906	23.32
15.62	107.38	7.81	3.99	7811	1.47
39.06	95.97	15.62	0.107	11717	0.12
78.1	83.22			15622	0.0023
152.2	98.66			23433	0.0018

The effective dose (IC_{50}) of prodrug **19** ist 2000 nM without addition of β -D-Glucosidase and >150 nM in the presence of β -D-Glucosidase. In presence of Cellulase results $IC_{50} = 1.9$ nM.

Results for α -D-Mannoside 22:

without α -D-Mannosidase		with α -D-Mannosidase (0.4 U/ml)	
concentration [nM]	Clone formation rate [%] pH = 7.4	concentration [nM]	Clone formation rate [%] pH = 7.4
0	100	0	100
1172	84.55	0.16	101.84
1562	75.77	0.39	77.08
2343	61.67	0.78	35.63
3124	40.60	1.17	12.55
3906	28.68	1.56	7.13
5468	13.52	2.34	2.3
7811	2.15	3.91	0.26
11717	0.206		

The effective dose (IC_{50}) of prodrug **22** ist 3300 nM without addition of α -D-Mannosidase and 2.1 nM in the presence of α -D-Mannosidase.

Results for α -L-Rhamnoside 23:

concentration [nM]	Clone formation rate [%]
	pH = 7.4
0	100
801	93.95
1602	98.87
2403	69.63
4006	43.14
5608	15.17
8011	2.73
12017	0.373
16022	0.043

The effective dose (IC_{50}) of prodrugs **23** is 3500 nM.

Results for β -D-Cellobioside 21:

without Cellulase		with Cellulase (0.17 U/ml)	
concentration [nM]	Clone formation rate [%] pH = 7.4	concentration [nM]	Clone formation rate [%] pH = 7.4
0	100	0	100
125	98.82	0.62	102.69
623	94.08	1.25	93.46
1870	73.58	3.12	41.19
3116	31.25	6.23	4.03
6230	2.86	12.46	0.55
9349	0.56	31.2	0.004
12465	0.127		

The effective dose (IC_{50}) of the prodrug **21** is 2400 nM without Cellulase and 2.6 nM in the presence of Cellulase.


Results for β -D-Lactoside 20:

Without enzyme		with Cellulase (0.17 U/ml)	
concentration [nM]	Clone formation rate [%] pH = 7.4	concentration [nM]	Clone formation rate [%] pH = 7.4
0	100	0	100
125	101.45	1.25	100.53
623	100.11	6.23	93.61
1870	85.59	12.46	62.49
3116	39.49	31.16	8.01
6230	3.83	62.23	1.07
9349	0.84	93.49	0.27
12465	0.44		

with Cellulase (0.17 U/ml) and β -D-Galactosidase (4 U/ml)		with β -D-Galactosidase (4 U/ml)	
concentration [nM]	Clone formation rate [%] pH = 7.4	concentration [nM]	Clone formation rate [%] pH = 7.4
0	100	0	100
0.62	90.59	0.62	101.64
1.25	79.6	1.25	102.22
3.12	29.67	3.12	93.46
6.23	3.67	6.23	101.05
9.35	0.51	9.35	94.63
12.46	0.36	12.46	91.71
31.16	0.018	31.16	100.47

The effective dose (IC_{50}) of prodrug **20** ist 2700 nM without addition of any enzyme and 14.5 nM in the presence of Cellulase, 2.1 nM in presence of Cellulase and β -D-Galactosidase and 31 nM in presence of only β -D-Galactosidase

Graphs of HTCFA *in vitro* results of all tested compounds




HPLC-MS: The analytical separation were realized using a Rheos 4000 solvent pump, a ERC-3415α degaser (*Flux Instruments*), a Jasco 851-AS autosampler and a *Thermo* diodearray-detector. The used column was a *phenomenex* Synergi Max-RP C12 (150 × 2 mm, particle size 4 µm) and the injection volume 5 µL. For handling, data collection and data evaluation we used the computer programs Janeiro and Xcalibur. The eluents were H₂O (solvent A) and Methanol (solvent B) of *VWR*. To enhance the peak shape 0.05% of formic acid (*Roth*) was added. The flow rate was 300 µL/min using the following gradients

Time [min]	A/B
0	70/30
0 – 15	70/30 → 0/100
15 – 22	0/100
22 – 23	0/100 → 70/30
23 – 29	70/30

The subsequent online analysis of the analytical separations was realized using ESI mass spectroscopy with an ion-trap-massspectrometer LCQ (*Finnigan*), the UV detection done between 200-800 nm and mass-detection between 100-2000 m/z. The temperature of the capillary was 220 °C, the spray-current 4.5 kV and the sheath-gas flow 80 (random unit).

HPLC-MS chromatograms


Glucose Prodrug (19):



Lactose Prodrug (20):

\Analytik-buero\Alles\bkLactosid0h


29.11.2007 10:31:19



Cellobiose Prodrug (21):

bkCellobiosid0h


29.11.2007 11:39:09



Mannose Prodrug (22):

\Analytik-buero\Alles\..\\bkmannosid0h

29.11.2007 14:33:21



Rhamnose Prodrugs (23):

\Analytik-buero\Alles\..\\bkrhamnosid0h

29.11.2007 15:40:13




Table of analytical data and purity criteria of target and other compounds

Compound or structure number	Known [citation given]	R _f	Optical rotation	¹ H NMR	¹³ C NMR	IR	UV-vis	MS	Copy of ¹ H/ ¹³ C NMR for SI	HR-MS	LC Purity
Acetylated Glucose Prodrug 13	–	X	X	X	X	X	X	X	X	X	–
Glucose Prodrug 19	–	X	X	X	X	X	X	X	X	X	98
Lactose Heptaacetate	X	X	–	X	X	–	–	–	–	–	–
Lactose trichloroacetyl midate 7	X	X	X	X	X	X	X	X	–	–	–
Acetylated Lactose Prodrug 14	–	X	X	X	X	X	X	X	X	X	–
Lactose Prodrug 20	–	X	–	X	X	X	X	X	X	X	99
Cellobiose Heptaacetate	X	X	–	X	X	–	–	–	–	–	X
Cellobiose trichloroacetyl midate 8	X	X	–	X	X	–	–	X	–	–	X
Acetylated Cellobiose Prodrug 15	–	X	X	X	X	X	X	X	X	X	X
Cellobiose Prodrug 21	–	X	–	X	X	X	X	X	X	X	100
Acetylated Mannose Prodrug 16	–	X	X	X	X	–	–	X	X	X	X
Mannose Prodrug 22	–	X	X	X	X	X	X	X	X	X	98
Acetylated Rhamnose Prodrug rac 17	–	X	–	X	X	–	–	–	X	X	X
Rhamnose Prodrug rac 23	–	X	X	X	X	X	X	X	X	X	96

Purity and Peak attributes of target prodrugs

Compound	HRMS [M+H] ⁺		Purity (%) ^a	HPLC Retention time (min.)
	Calculated	Found		
19	640.24202	640.24194	98.1	4.26
20	802.29484	802.29496	99.0	4.15
21	802.29484	802.29482	99.8	4.17
22	640.24202	640.24211	98.4	4.55
23	624.24710	624.24707	96.4	5.48

^a Purity was assessed by integration of relevant peak areas from UV trace from 200-800 nm.